• Alphyn Biologics

  Participated · Series B · Dec 2025

  Alphyn Biologics is a clinical-stage dermatology firm advancing first-in-class Multi-Target Therapeutics based on its Zabalafin Platform. Its lead product, Zabalafin Hydrogel, is designed to simultaneously address the multiple drivers of atopic dermatitis (inflammation, itch, bacteria and dry skin) and molluscum contagiosum virus (virus, itch, inflammation, dermatitis and secondary bacterial infection). The topical candidate aims to provide superior efficacy, better tolerability and the potential for sustained disease control compared with single-target treatments. With the new funding, Alphyn plans to run a global Phase 2b trial in atopic dermatitis, launch a Phase 2 program in molluscum contagiosum and scale its raw-material supply. The company became operational in 2020 and maintains offices in Annapolis, Maryland and Cincinnati, Ohio, with subsidiaries in Australia and Austria. Including the latest round, Alphyn has raised roughly $34 million to date to build a pipeline of dermatologic therapeutics.

• Cordance Medical

  Participated · Seed · Nov 2025

  Cordance Medical is building a noninvasive focused ultrasound system designed to temporarily and safely open the blood-brain barrier (BBB), enabling drugs and other therapeutic agents to reach the brain more effectively. The platform employs patient-specific signal processing with real-time monitoring of BBB opening and avoids the need for head fixation or live imaging, targeting practical outpatient use. While its first clinical application is brain cancer, the company envisions broader utility across multiple neurological conditions. Cordance has already secured FDA Breakthrough Device Designation in neuro-oncology and received a grant from the National Cancer Institute at the NIH to help fund its first-in-human U.S. trial. Proceeds from its recent seed financing will advance this clinical study and further product development. Based in Mountain View, California, the firm is supported by a strong syndicate of healthcare and neuro-oncology investors. The company has not disclosed revenue, user numbers, or other operating metrics.

• PanTher Therapeutics

  Participated · Series A · Jun 2021

  PanTher Therapeutics develops a proprietary platform that enables direct, localized, and sustained delivery of proven and novel therapeutic agents to solid tumors. The underlying technology was developed at MIT and subsequently in‑licensed by PanTher. Its lead candidate is designed to control tumor progression in pancreatic cancer, improve survival, and is easily integrated into a commonly used, minimally invasive staging procedure. The company says the platform can be adapted to treat additional solid tumor indications and aims to unlock a drug’s full potential while reducing systemic toxicity. PanTher closed an oversubscribed $5.4M Series A led by Catalyst Health Ventures with participation from Angel Physicians Fund and other investors, bringing total funding to $7.4M. Proceeds from the financing will support the company’s first‑in‑human clinical trial as it transitions to a clinical‑stage company. The company also expanded its board with Darshana Zaveri (CHV), Manish Bhandari (APF), and Maria Palasis (Lyra Therapeutics).

• Elucid

  Participated · Series A · May 2021

  Elucid's core product, PlaqueIQ, is an AI-powered computed tomography angiography (CTA) analysis software that objectively quantifies and characterizes arterial plaque and is FDA-cleared. The software simulates histology and is validated against tens of thousands of tissue annotations by pathologists. Elucid is pursuing an additional indication for non-invasive fractional flow reserve measurement (FFRCT) uniquely derived from its PlaqueIQ technology. The plaque analysis software is commercially available in the U.S., UK, EU, and South Korea. The company has been ramping commercial efforts, expanding clinical research and development, and has significantly bolstered its leadership team. Financially, Elucid announced an $80 million Series C and has raised $121 million in total funding since inception. Elucid builds interpretable, validated AI software that non-invasively quantifies atherosclerotic plaque characteristics compared to histopathology, including lipid rich necrotic core. Its machine-learning algorithms characterize tissue types in the artery wall and power applications that derive FFRct, estimate risk of heart attack/stroke, and produce expression-prediction outputs to inform therapeutic selection. The platform enables physicians to diagnose causes of chest pain and detect early-stage heart disease not visible with alternative methods. The software is FDA-cleared and CE-marked and is commercially available in the U.S., Europe, and South Korea. Led by CEO Blake Richards, the company intends to use new funding to accelerate growth and further development efforts. No revenue or user metrics were reported in the article. Elucid develops interpretable, validated AI software (ElucidVivo) to help physicians detect cardiovascular disease and optimize treatment decisions. ElucidVivo is the first FDA-cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics versus histopathology, including lipid-rich necrotic core, and is commercially available in the U.S. and Europe. The company has published studies on deriving fractional flow reserve (FFRct) from vasodilative vessel-wall capacity and on estimating coding and non-coding RNA transcripts (“Virtual Transcriptomics”). Management says the technology aims to reduce invasive procedures, improve diagnostic power, and enable precision medicine for cardiac and neurovascular patients. Recent hires include Jason Bottiglieri as Chief Commercial Officer and Murali Ayyapillai as Vice President of Engineering to support commercialization and product development. The company plans to continue advancing and commercializing its platform to improve outcomes and reduce healthcare costs.

• Foldax

  Participated · Series D · Jun 2020

  Foldax is developing the Tria biopolymer heart valve, which combines a proprietary LifePolymer material with an innovative design intended to eliminate calcification and avoid lifelong anticoagulants. Tria is described in the article as the first and only heart valve to be robotically manufactured, a process the company says reduces variability and improves precision, repeatability, quality and manufacturing economics. The company is developing both surgical aortic and mitral valves and a transcatheter aortic valve replacement (TAVR) device. Foldax plans to add patients to its recently completed EFS clinical trial for the surgical aortic Tria valve, initiate and enroll patients in the surgical mitral valve trial, and advance the TAVR device toward a first-in-man clinical study. Foldax is developing the Tria technology in partnership with Caltech and CSIRO and is headquartered in Salt Lake City, Utah.

No current team members are available.